Business
CareDx Showcases Latest Innovation in Transplantation at European EFI 2022 Conference
Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant MonitoringSOUTH SAN
About this update from Caredx, Inc.
[{"type":"text","content":"Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant MonitoringSOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will be presenting the latest information on its AlloSeq® portfolio of pre- and post-transplant solutions for human leukocyte antigen (HLA) typing, including QTYPE®, and post-transplant hematopoietic stem cell and organ transplant surveillance during poster presentations and the symposium taking place at this year’s EFI 2022 Conference. The joint 2022 European Federation for Immunogenetics (EFI) and Histocompatibility Conference takes place from May 17 to May 20 in Amsterdam, the Netherlands. “CareDx is a global leader in transplant, and Europe is our largest commercial presence outside the U.S. As such, we are proud to bring innovative, best-in-class solutions to researchers, laboratories, and clinicians in Europe with our AlloSeq franchise, including AlloSeq Tx17 and Tx9 for HLA typing, AlloSeq cfDNA for organ transplant monitoring, and AlloSeq HCT for hematopoietic stem cell monitoring research,” said Reg Seeto, CEO and President of CareDx. “There are few companies 100% dedicated to transplant, which is what makes CareDx’s mission and commitment so unique and important for transplant patients.” CareDx will be on hand to showcase its leadership in serving European laboratories, researchers, and clinicians with its leading product portfolio of next-generation sequencing (NGS) based AlloSeq products, which serve pre- and post-transplantation. For pre-transplant, CareDx offers HLA typing solutions, QTYPE, AlloSeq Tx17, and newly introduced AlloSeq Tx9, covering 9 key HLA loci. For post-transplantation monitoring, CareDx offers AlloSeq HCT chimerism testing using NGS for research use only and AlloSeq cfDNA for labs to assess transplanted organ health. Additionally, CareDx provides pre-transplant HLA typing and post-transplant surveillance testing for customers wanting to use its service lab in Stockholm, Sweden, for clinical research. “Together with CareDx, we are working on several projects f...